| 0.655 0.034 (5.51%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.89 |
1-year : | 1.04 |
| Resists | First : | 0.76 |
Second : | 0.89 |
| Pivot price | 0.62  |
|||
| Supports | First : | 0.6 |
Second : | 0.5 |
| MAs | MA(5) : | 0.63 |
MA(20) : | 0.63 |
| MA(100) : | 1.16 |
MA(250) : | 2.46 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 52.3 |
D(3) : | 52.1 |
| RSI | RSI(14): 46.1 |
|||
| 52-week | High : | 5.25 | Low : | 0.41 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RENB ] has closed below upper band by 38.0%. Bollinger Bands are 64.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.66 - 0.66 | 0.66 - 0.66 |
| Low: | 0.59 - 0.6 | 0.6 - 0.6 |
| Close: | 0.65 - 0.66 | 0.66 - 0.66 |
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.
Wed, 13 Mar 2024
Renovaro Biosciences Appoints Simon Tarsh as Interim CFO - TipRanks
Mon, 11 Mar 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENB - PR Newswire
Sun, 18 Feb 2024
Enochian Biosciences Inc. Announces its Completion of FDA INTERACT Meeting for a Potential Cure for HIV - Marketscreener.com
Sun, 18 Feb 2024
Enochian Biosciences Announces the Appointment of Greg Alton as Lead Independent Board Member - Marketscreener.com
Wed, 14 Feb 2024
Hit With Short Seller Report, Renovaro Biosciences Comments On Hindenburg's Opinion Piece - Yahoo Finance
Tue, 13 Feb 2024
AI Pioneer GEDi Cube and Biotech Innovator Renovaro - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 154 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 24.9 (%) |
| Held by Institutions | 9.6 (%) |
| Shares Short | 3,420 (K) |
| Shares Short P.Month | 3,970 (K) |
| EPS | -0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.91 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -12.1 % |
| Return on Equity (ttm) | -87.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -0.82 |
| PEG Ratio | 0 |
| Price to Book value | 0.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|